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Erythropoietic protoporphyria (EPP) is an inherited disorder of heme biosynthesis that results from a partial
deﬁciency of ferrochelatase (FECH). Recently, we have shown that the inheritance of the common hypomorphic
IVS3-48C allele trans to a deleterious mutation reduces FECH activity to below a critical threshold and accounts
for the photosensitivity seen in patients. Rare cases of autosomal recessive inheritance have been reported. We
studied a cohort of 173 white French EPP families and a group of 360 unrelated healthy subjects from four ethnic
groups. The prevalences of the recessive and dominant autosomal forms of EPP are 4% (95% conﬁdence interval
1–8) and 95% (95% conﬁdence interval 91–99), respectively. In 97.9% of dominant cases, an IVS3-48C allele is
coinherited with the deleterious mutation. The frequency of the IVS3-48C allele differs widely in the Japanese
(43%), southeast Asian (31%), white French (11%), North African (2.7%), and black West African (!1%) pop-
ulations. These differences can be related to the prevalence of EPP in these populations and could account for the
absence of EPP in black subjects. The phylogenic origin of the IVS3-48C haplotypes strongly suggests that the
IVS3-48C allele arose from a single recent mutational event. Estimation of the age of the IVS3-48C allele from
haplotype data in white and Asian populations yields an estimated age three to four times younger in the Japanese
than in the white population, and this difference may be attributable either to differing demographic histories or
to positive selection for the IVS3-48C allele in the Asian population. Finally, by calculating the ratio inK /KA S
humans and chimpanzees, we show that the FECH protein sequence is subject to strong negative pressure. Overall,
EPP looks like a Mendelian disorder, in which the prevalence of overt disease depends mainly on the frequency of
a single common single-nucleotide polymorphism resulting from a unique mutational event that occurred 60,000
years ago.
Received June 24, 2005; accepted for publication October 3, 2005; electronically published November 15, 2005.
Address for correspondence and reprints: Dr. J.C. Deybach, Centre Franc¸ais des Porphyries, Hoˆpital Louis Mourier, 178 rue des Renouillers
92701 Colombes CEDEX, France. E-mail: jc.deybach@wanadoo.fr
Am. J. Hum. Genet. 2006;78:2–14.  2005 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7801-0003$15.00
Complex phenotype/genotype relationships in simple
Mendelian disorders have often been attributed to en-
vironmental factors or to modiﬁer genes that modulate
the clinical expression of a gene defect at a major locus.
An alternative hypothesis is that, in some dominantly
inherited disorders, clinical manifestations are not sim-
ply a matter of haploinsufﬁciency and that some addi-
tional deﬁciency may be necessary for the phenotype to
be expressed (Delaunay 2002; Emison et al. 2005). In
these disorders, slight differences in the expression of the
normal allele in trans to the mutated allele may have a
major impact on the clinical expression of the disease
by reducing gene expression below a critical threshold.
The penetrance of a dominant mutation may thus be
modulated by functional polymorphisms occurring at
the same locus.
Erythropoietic protoporphyria (EPP) (MIM 177000)
is an inherited disorder due to a partial deﬁciency of
ferrochelatase (FECH) (EC 4.99.1.1.), the ﬁnal enzyme
in the heme biosynthesis pathway (Anderson et al.
2001). FECH is an inner membrane mitochondrial en-
zyme that catalyzes the insertion of ferrous iron into
protoporphyrin IX to form heme. FECH deﬁciency in
bone marrow erythroid cells is responsible for the over-
production and accumulation of protoporphyrin IX in
erythrocytes, which leads to a secondary accumulation
of protoporphyrin in the plasma, skin, bile, and feces
(Anderson et al. 2001). The most common clinical man-
ifestation is lifelong acute photosensitivity of the skin in
response to exposure to the sun, which develops early
in childhood. Although EPP is generally a benign con-
dition, hepatic complications, such as cholelithiasis or,
in rare cases (∼2%), cirrhosis and even rapidly fatal liver
disease, may occur (Bloomer 1988; Doss and Frank
1989; Todd 1994; Meerman 2000). EPP cases have been
reported in Europe, the United States, and Japan. So far,
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to our knowledge, no case of EPP has been reported in
a black African subject.
More than 85 mutations in the FECH gene, including
missense, nonsense, splicing, deletions, and insertions,
have been identiﬁed in EPP families (ﬁg. 1A) (Ru¨fenacht
et al. 1998; Yotsumoto et al. 2001; Chen et al. 2002;
Yasui et al. 2002; Wiman et al. 2003; Onaga et al. 2004;
Whatley et al. 2004; Human Gene Mutation Database).
EPP is characterized by a high allele heterogeneity, al-
though some founder mutations have been reported in
Swiss patients (Ru¨fenacht et al. 1998). Most individuals
who are heterozygous for these mutations are asymp-
tomatic, despite having FECH activity levels that are
only half the normal value (Nordmann and Deybach
1990). For protoporphyrin to accumulate sufﬁciently to
cause photosensitivity, FECH activity has to fall below
a critical threshold of ∼35% of the normal level (Bon-
kowsky et al. 1975; Rossi et al. 1988; Nordmann and
Deybach 1990).
On the basis of enzymatic assays and molecular anal-
ysis in EPP families, two modes of inheritance have been
proposed. In rare cases, the disorder is transmitted as
an autosomal recessive trait, with both parents trans-
mitting a molecular defect to the affected children, who
typically have a residual lymphocyte FECH activity of
!10% of normal (Deybach et al. 1986; Norris et al.
1990; Lamoril et al. 1991; Sarkany et al. 1994; Goerz
et al. 1996; Whatley et al. 2004). So far, to our knowl-
edge, only seven cases of autosomal recessive transmis-
sion have been documented (Lamoril et al. 1991; Sar-
kany et al. 1994; Poh-Fitzpatrick et al. 2002; Whatley
et al. 2004). In most cases, the inheritance of EPP is
described as an autosomal dominant disorder with in-
complete penetrance. We have recently demonstrated
that patients with the dominant form usually share a
hypomorphic allele that is common in the general pop-
ulation in trans to a rare loss-of-function allele (Went
and Klasen 1984; Gouya et al. 1996, 1999, 2002). A
common intronic SNP, IVS3-48C, is responsible for the
low expression of the hypomorphic allele by modulating
the use of a constitutive cryptic acceptor splice site; the
aberrantly spliced mRNA is degraded by a nonsense-
mediated decay mechanism, leading to a lower steady-
state level of FECH mRNA. In overt cases, this low
steady-state level of normal mRNA results in an addi-
tional FECH enzyme deﬁciency, which is necessary for
protoporphyrin overproduction and photosensitivity to
occur (Gouya et al. 2002).
In this article, we report our study of two large cohorts
of white French (WF) EPP families and a control group
of 360 unrelated healthy subjects from four different
ethnic groups.We ﬁrst established the relative prevalence
of the autosomal recessive versus the dominant forms
and, then, in the dominant form, we identiﬁed the dif-
ferent mechanisms that underlie the incomplete pene-
trance of FECH mutations. We then studied the IVS3-
48T/C polymorphism in different populations, inves-
tigating the relationship between IVS3-48C allele prev-
alence and overt EPP occurrence. Finally, we focused our
attention on the phylogenic origin of the IVS3-48C allele
and estimated when the IVS3-48C allele ﬁrst appeared.
Subjects, Material, and Methods
Study Subjects
We investigated a ﬁrst cohort of 241 subjects from 113 WF
EPP families recruited at the Centre Franc¸ais des Porphyries
between 1990 and 2004 (ﬁg. 2). The 241 subjects consisted
of 113 overt patients with a typical history of skin photosen-
sitivity and a high level of free protoporphyrin in their eryth-
rocytes (32,443  21,243 [mean  SD] nM; normal !1,900
nM) plus 128 clinically unaffected relatives. We assayed pe-
ripheral lymphocyte FECH enzyme activity in 95 of the 113
overt patients. Family studies (nuclear or extended families)
allowed us to perform an IVS3-48T/C segregation analysis in
53 cases.
The second cohort consisted of 60 nuclear ( ) or ex-np 25
tended ( ) French EPP families, who were recruited atnp 35
the Centre Franc¸ais des Porphyries between 1975 and 2000
and had well-documented clinical histories and FECH enzyme
activity levels, which allowed us to assess the correlation be-
tween the IVS3-48C allele frequency and the prevalence of
overt EPP. These families were independent of the 113 de-
scribed above, and their EPP diagnosis was based on clinical
data and the measurement of lymphocyte FECH activity (overt
EPP patients, 1.5  0.39 [mean  SD] nM) and erythrocyte
protoporphyrin levels (overt EPP patients, 36,840  44,468
[mean SD] nM). No DNAwas available from these subjects.
Available for study were 361 subjects consisting of 60 pro-
bands, 152 relatives whose lymphocyte FECH activity was at
least 50% below normal, and 149 relatives whose lymphocyte
FECH activity was in the normal range. The 301 relatives were
distributed across 100 different generations.
Three hundred sixty subjects unrelated to EPP patients were
studied: 80 WF; 75 North Africans (NA) originating from
Algeria, Morocco, or Tunisia; 115 southeast Asians (SEA) orig-
inating from Vietnam, Cambodia, or Shanghai, China; and
100 black West Africans (WA) originating from Cameroon,
the Ivory Coast, or Nigeria.
These procedures involving human subjects were performed
in accordance with the 1983 revision of the Declaration of
Helsinki, and the study was approved by the Hospital Ethics
Committee of Hoˆpital Ambroise Pare´, in Paris.
Characterization of the Speciﬁc FECH Mutation
Genomic DNA was extracted from peripheral blood leu-
kocytes with the use of a QIAamp DNA puriﬁcation kit (Qia-
gen). All coding regions, the intron/exon junctions with 200–
300 bp ﬂanking sequence, 1.3 kb of 5′ noncoding region, and
the two polyadenylation signal regions were PCR ampliﬁed
and subjected to direct sequencing using ﬂuorescent ddNTPs
(BigDye) and an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems). Primers and conditions are available from the
Figure 1 A, Exon/intron organization of the human FECH gene and reported mutations responsible for EPP. Previously unreported
mutations are shown in bold. B, Differences between human and chimpanzee cDNA. Bold vertical lines denote exons, and unbroken lines
denote introns. cp cDNA Sequence (human [GenBank accession number NM000140]; chimpanzee [GenBank accession number DQ149645]).
p p Protein sequence (GenBank accession number NP000131). g p FECH Gene sequence (GenBank accession number AJ250235).
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Figure 2 Schematic representation of the clinical, enzymatic, and molecular data of the 95 EPP families for which both FECH enzyme
activity and gene defect were available. Wt p Wild-type allele; M pFECH-Mutated allele.
corresponding author on request. The presence or absence of
mutations was conﬁrmed by the sequencing of both strands.
We also sequenced DNA samples from three chimpanzees (Pan
troglodytes), using the same set of primers (GenBank accession
number DQ149645).
Intragenic Polymorphism Genotyping
We analyzed the 12 intragenic SNPs distributed over the
FECH gene: ss46563186, ss46563187, ss46563188, and
rs17063905 are located in the promoter region; rs2269219
is in intron 1; ss46563189 is in intron 2; IVS3-48T/C
(rs2272783) is in intron 3; ss46563190 is in intron 4;
ss46563191 is in intron 5; ss46563192 and ss46563193 are
in intron 9; and rs8339 is in the noncooling region of exon
11. Human FECH genomic DNA and cDNA are numbered
in accordance with the reference sequences, with GenBank ac-
cession numbers AJ 250235 and NM000140, respectively,
with the A of the ATG initiation codon shown as “1.” The
symbols used to designate genes in this article follow the guide-
lines of the HUGO Gene Nomenclature Committee (Povey et
al. 2001). After PCR ampliﬁcation of the appropriate frag-
ments, PCR products were digested with HinfI, HaeII, DdeI,
AluI, Cac8I, NlaIII, TseI, BstNI, BsrI, BsmAI, and TaqIa re-
striction enzymes. SNP genotyping of rs8339 was performed
using denaturing gradient gel electrophoresis, as described else-
where (Gouya et al. 1999). All primers and conditions are
available on request. IVS3-48T/C data for the Japanese pop-
ulation were provided by Nakamura Yusuke (Human Genome
Center, Institute of Medical Science, University of Tokyo) and
are available in the dbSNP.
Haplotype Analysis
Haplotypes were estimated from unphased genotypes by use
of the expectation maximization (EM) algorithm included in
the software package ARLEQUIN ver 2.000 (Schneider et al.
1997). Phylogenetic analysis of the individual haplotypes used
the minimal spanning network included in ARLEQUIN.
Lymphocyte FECH Enzyme Assay and Erythrocyte
Protoporphyrin Measurements
FECH activity was determined by ﬂuorometricmeasurement
of zinc-mesoporphyrin formation after incubation for 60 min
at 37C, as established by Li et al. (1987), but with some
modiﬁcations. For routine assays, a peripheral lymphocyte ho-
mogenate was prepared in 50 mM Tris-HCl (pH 7.6) and 20%
glycerol, and the protein concentration was measured using
the Bradford method (Bio-Rad reagents). The reaction con-
sisted of a 5-min preincubation at 37C, with 200 ml of lym-
phocyte homogenate, 200 ml of incubation buffer (250 mM
Tris-HCl [pH 7.6], 1% [v/v] Triton X-100, and 1.75 mM pal-
mitic acid), and 40 ml of 0.5-mM mesoporphyrin (ﬁnal con-
centration 43 mM). Then, 20 ml of 1-mM zinc acetate solution
was added (ﬁnal concentration 43 mM), and the incubation
continued for a further 60 min. A blank was prepared without
the cell homogenate. The reaction was stopped by the addition
of a dimethyl sulfoxide/methanol mixture (30:70 [v/v]). After
it was centrifuged, the supernatant was transferred to a ﬂuo-
rometry cell, and the ﬂuorescence was measured at 580 nm,
with an excitation wavelength of 410 nm. The enzymatic ac-
tivity was expressed as nanomoles of zinc-mesoporphyrin
formed per hour per milligram of protein at 37C (normal
valuep 4.83 0.91 [mean SD] nmol mesozinc/h/mg). The
erythrocyte protoporphyrin was determined by standardmeth-
ods (Deacon and Elder 2001).
Statistical Analysis
The Student t test or the Mann-Whitney test was used to
compare group means of continuous data. Standard deviations
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Table 1
EPP Patients with Compound Heterozygotism for Two Rare FECH Alleles
Patient
FECH
Activitya
Erythrocyte
Protoporphyrinb Allele 1 Allele 2
P1 0.2 50,000 S222G, IVS3-48C D274N, IVS3-48T
P2 0.5 50,000 P192T, IVS3-48T D283G, IVS3-48T
P3 0.5 60,000 G55C, IVS3-48T M267I, IVS3-48T
P4 0.3 26,000 D274N, IVS3-48T L384S, IVS3-48T
P5 1.4 4,800 IVS8-2ArG, IVS3-48T Y191H, IVS3-48T
a In nanomoles of mesozinc/hour/milligram of protein at 37 C,measured in peripheral
lymphocytes (normal value [mean  SD] p 4.83  0.91 ).
b In nanomoles/liter ( ).N ! 1,900
were calculated for group means. The genotype distribution
of the 12 polymorphisms in the WF, WA, and SEA populations
and for the IVS3-48T/C SNP in the NA population satisﬁed
the Hardy-Weinberg equilibrium ( test, ).2x P 1 .5
Estimate of the Age and Growth Rate of the IVS3-48C
Mutation
We performed a joint estimate of these quantities, using the
method developed by Austerlitz et al. (2003). This method
provides a joint estimate of the age of the mutation—that is,
the time elapsed since the appearance of the common ancestor
of the mutation carriers in the population and the growth rate
of the number of copies since this appearance. This common
ancestor can be either a new mutant or a migrant who brought
the gene into the population or the only individual who left
offspring carrying this mutation in the present population be-
cause of a bottleneck. Four different populations were studied:
the 80 WF subjects, the 92 Chinese from the SEA population,
the 50 parents from 25 fully genotyped EPP families, and the
44 Japanese subjects from the International HapMap Project.
Results
Mutation Analysis
We conducted a FECH molecular study on 113 overt
EPP patients available between 1990 and 2004 from the
Centre Franc¸ais des Porphyries. Twenty-ﬁve of these EPP
patients had already been studied and reported but were
re-evaluated here for the IVS3-48T/C polymorphism
(Lamoril et al. 1991; Ru¨fenacht et al. 1998; Gouya et
al. 1996, 1999, 2002), and 88 new cases were investi-
gated. The 88 new patients were subjected to the direct
sequencing of all coding regions, the intron/exon junc-
tions, the 1.3-kb upstream promoter region, and the two
polyadenylation signal regions. In 18 overt patients
(15.9%), we were not able to identify any FECH gene
defect, even though the clinical manifestations, the eryth-
rocyte protoporphyrin level, and the FECH enzyme
activity closely matched EPP. The possibility that the
entire gene had been deleted was excluded by the evi-
dence that they were heterozygous for at least two in-
tragenic SNPs. Of the 95 patients in whom gene defects
were identiﬁed, 90 were heterozygous for a FECH
mutation and 5 displayed compound heterozygosity.
Twenty-seven previously unreported mutations were
identiﬁed (ﬁg. 1A and table 1). These were highly het-
erogeneous and usually family speciﬁc. The predominant
type of mutations were missense mutations in the coding
regions (36.4%), followed by intronic mutations pre-
dicting anomalous RNA splicing (24.2%), small dele-
tions and insertions (21.2%), and nonsense mutations
(15.2%). Most of the mutations produced null alleles.
This distribution is similar to previously published EPP
mutation patterns (Ru¨fenacht et al. 1998; Schneider-Yin
et al. 2000).
FECH Enzyme Assay
In the 18 overt patients in whom mutation testing
failed to identify any gene defect, enzyme activity was
60%–70% below normal, and this enzyme deﬁciency
was always shown to be transmitted through two to
three generations, which allowed us to detect asymp-
tomatic carriers in family studies. To evaluate the ac-
curacy of lymphocyte FECH activity assay in EPP di-
agnosis, we also compared the FECH enzymatic data to
the molecular data in the 95 cases for which both sets
of data were available. In these families, lymphocyte
FECH activity was measured in 223 subjects: 95 pro-
bands, 61 relatives carrying a FECH gene defect, and
67 mutation-free subjects (ﬁg. 2). The 156 individuals
carrying at least one FECH gene defect displayed 50%–
90% lower FECH activity than the normal control
group (ﬁg. 3). The lowest FECH activities were observed
in patients with two molecular defects (ﬁgs. 2 and 3;
0.375  0.15 [mean  SD] nmol mesozinc/h/mg of
protein at 37C), and asymptomatic carriers showed
higher activity ( nmol mesozinc/h/mg) than2.42 0.41
overt patients ( nmol mesozinc/h/mg,1.45 0.32 P !
). In addition, when the 67 relatives without the410
FECH mutation were classiﬁed according to their IVS3-
48T/C genotype, we found that the subjects who were
IVS3-48T/T homozygous ( nmol mesozinc/5.03 0.66
h/mg) had higher FECH activity than those who were
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Figure 3 Peripheral lymphocyte FECH activity (nanomoles of
mesozinc/hour/milligram of protein at 37C) in six different groups
are represented as box plots showing the median, the quartiles, and
the 90th and the 10th percentiles. Additionally, the mean SD values
are as follows: control group, 4.83  0.91; IVS3-48T/T healthy rel-
ative group, 5.03  0.66; IVS3-48T/C healthy relative group, 4.20
 0.60; asymptomatic carrier group, 2.42  0.41; symptomatic pa-
tient group with the dominant form, 1.45  0.32; and symptomatic
patient group with the recessive form, 0.375  0.15.
IVS3-48T/C heterozygous ( nmol mesozinc/4.20 0.60
h/mg, ).4P ! 10
EPP Inheritance
Four EPP families displayed clear recessive inheritance
(ﬁg. 2). These patients presented with !10% residual
lymphocyte FECH activity, and this was associated with
two FECH gene defects (ﬁg. 2 and table 1). The FECH
gene segregation study shows that each of the parents
of these patients presents one mutant allele associated
with an ∼50% decrease in FECH activity (data not
shown). The four patients (P1, P2, P3, and P4) (table 1)
were found to be compound heterozygotes for missense
mutations. Two mutations (P192T and D383G) had
previously been reported in dominant EPP, and a novel
one, D274N, was found twice (in P1 and P4) in this
study.
On the basis of molecular and enzymatic data, 90 EPP
families displayed a clear autosomal dominant form,
with a single molecular FECH defect associated with
30%–40% residual FECH activity (ﬁg. 2).
Unexpectedly, we identiﬁed compound heterozygosity
in one patient (P5) with 30% residual FECH activity
(ﬁg. 2 and table 1). Overt patient P5 had two trans
mutations: an IVS8-2ArG on one allele, disrupting the
consensus acceptor splice site of intron 8, and a Y191H
substitution on the other. Both of these mutations are
unique to this family. The expression in the prokaryotic
system of the missense Y191H mutation shows 72%
residual FECH activity when compared with the normal
human cDNA construct (Ru¨fenacht et al. 1998). With
the assumption that the IVS8-2ArG mutation is re-
sponsible for the exon 8 skipping, resulting in complete
loss of function, and that the Y191H substitution de-
creases the allelic FECH activity by 28%, in a diploid
system the global residual FECH activity should be
∼35%. This is, indeed, in the same range as the activity
found in this patient’s P5 lymphocytes (table 1). Both
parents are IVS3-48T homozygous. In agreement with
molecular data, the parent transmitting the IVS8-2ArG
mutation displays a 50% decrease in FECH activity, and
the parent carrying the Y191H mutation has a FECH
activity in the normal range (4.6 nmol mesozinc/h/mg
of protein at 37C) compared with the control group
(4.83  0.91 [mean  SD] nmol mesozinc/h/mg) (ﬁg.
3).
Altogether, 90 patients (90/95: 95% [95% CI 91–99])
presented with autosomal dominant EPP, and 4 (4/95:
4% [95% CI 1–8]) presented with autosomal recessive
EPP. The classiﬁcation of patient P5 is controversial and
depends on whether one considers the mutation data or
the enzyme data (ﬁg. 2).
Prevalence of the FECH IVS3-48C Allele in Patients
with Overt EPP and in Asymptomatic Carriers
Haplotyping studies of the 113 overt EPP patients and
of the 61 asymptomatic carriers showed that none of
the 61 asymptomatic carriers had the IVS3-48C poly-
morphism. In contrast, 93 of 95 overt patients with a
dominant form of EPP did have an IVS3-48C allele.
Three of the four EPP patients with recessive inheritance
are IVS3-48T homozygous, and one is IVS3-48T/C het-
erozygous (ﬁg. 2). Fifty-three nuclear EPP families were
available for a segregation study of the FECH alleles.
This demonstrated that the vast majority of overt pa-
tients present an IVS3-48C polymorphism in trans to
the mutant FECH gene. No IVS3-48C allele was found
in the P5 family and in two families with dominant EPP
(FECH gene mutations: IVS9-2ArG and C411G). We
were unable to identify any additional mutations in the
two remaining families, but, in one patient, clinical man-
ifestations of the disease appeared belatedly at the age
of 30 years, just after the patient experienced partial
hepatic resection for multiple hepatic adenomas attrib-
uted to prolonged exposure to contraceptive pills (ﬁg.
2).
Prevalence of IVS3-48C Polymorphism in WF, NA,
WA, and SEA Populations
We determined the genotype of the IVS3-48T/C poly-
morphism of 80 WF, 75 NA, 115 SEA, and 100 WA
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Table 2
FECH IVS3-48T/C Polymorphism in WF, NA, WA, SEA, and
Japanese Populations
POPULATION
NO. OF
SUBJECTS
NO. OF SUBJECTS
WITH GENOTYPEa
NO. (%) OF
ALLELES
C/C C/T T/T C T
WF 80 0 18 62 18 (11.3) 142
NA 75 0 4 71 4 (2.7) 146
WA 100 0 1 99 1 (!1) 199
SEA 115 16 39 60 71 (31.0) 159
Japanb 549 NA NA NA 475 (43.3) 623
a NA p Not available.
b Human Genome Center, Institute of Medical Science, University
of Tokyo.
subjects. Table 2 shows that there are major differences
between the four populations studied, with regard to
their IVS3-48T/C polymorphism frequency. We identi-
ﬁed a north-south gradient from 11.3% in the WF pop-
ulation to 2.7% in the NA population and to !1% in
WA subjects. In the SEA population, the IVS3-48C allele
occurs at a high frequency (31%).
Correlation between IVS3-48C Allele Frequency and
Overt EPP Prevalence
To conﬁrm that the penetrance of EPP mutations in
the WF population was, indeed, determined by the fre-
quency of the IVS3-48C hypomorphic allele, we studied
a second set of EPP families ( ; see “Study Sub-np 60
jects” subsection). Usingmultigenerational pedigrees,we
estimated the number of cases in which one or several
EPP patients were found in generations different from
that of the probands. When two or more siblings were
affected, only one was considered in the model. This led
us to count nine occurrences in 100 generations. With
the assumption that the coinheritance of a FECH gene
defect and a low-expression IVS3-48C FECH allele is
required to have overt clinical manifestations of the dis-
ease, the theoretical number of occurrences with at least
one overt patient in 100 generations in EPP families
should be . This theoretical value is100# 11%p 11
close to the nine subjects with overt EPP patients found
in our set of 60 EPP families (binomial law, ).Pp .11
IVS3-48C FECH Alleles: Haplotypic and Phylogenic
Analyses
Twelve polymorphisms were used in the SEA,WF, and
WA populations to construct haplotypes estimated by
the EM algorithm. All SNPs were found to comply with
the Hardy-Weinberg equilibrium. Twenty-two IVS3-
48C haplotypes were assigned from unphased genotype
data, but most of them had a frequency of !1% (data
not shown) and were not taken into consideration. The
ﬁve most common haplotypes (HC1–HC5) are shown
in table 3. Haplotypes HC1, HC2, and HC3 and hap-
lotypes HC1, HC2, HC4, and HC5 account for most of
the IVS3-48C haplotypes found in the SEA andWF pop-
ulations, respectively (table 3). Haplotypes HC1 and
HC2 occur in both the SEA and WF populations but at
different frequencies. Haplotype HC1 is, by far, the most
frequent in the SEA population (23% of all haplotypes
and 71% of IVS3-48C haplotypes) but occurs at a much
lower frequency in the WF population (1.2% of all hap-
lotypes and 12% of IVS3-48C haplotypes) and in the
only WA subject to display a IVS3-48C polymorphism.
The HC1 haplotype differs from the closest African hap-
lotype (root haplotype [RH] in table 3) at three sites,
two of them being monomorphic in the WA population
(ss46563187 and IVS3-48T/C [table 3]). Haplotype
HC2 occurs in SEA with a 5% frequency of IVS3-48C
haplotypes (1.7% of all SEA haplotypes) and 13% in
WF (1.3% of all WF haplotypes). Haplotypes HC3,
HC4, and HC5 are population speciﬁc. We then per-
formed a phylogenic analysis of the IVS3-48C haplo-
types. We found that most of the 22 IVS3-48C haplo-
types, and especially the ﬁve most common IVS3-48C
haplotypes, are closely related to each other. Haplotype
HC1 represents the consensus haplotype and was pro-
gressively shown to be connected to haplotypes HC2 to
HC5, either by single-site difference (using the minimum
spanning network algorithm implemented in ARLE-
QUIN ver. 2.000) or by recombination events between
IVS3-48C and IVS3-48T haplotypes. In the most par-
simonious model, one single-site mutation and three re-
combinations between IVS3-48C and IVS3-48T hap-
lotypes explain the HC1 to HC5 phylogeny, as proposed
in ﬁg. 4. IVS3-48C haplotypes may originate from a very
frequent (9%) WA RH (table 3 and ﬁg. 4).
Estimation of the Date of the Appearance of the IVS3-
48C Mutation
We calculated the date of the most recent common
ancestor of IVS3-48C haplotypes, using four different
data sets. With two of them, those of the WF population
and the WF EPP families, the age of the allele was es-
timated to be ∼40,000–60,000 years. In contrast, the
estimate calculated from the Japanese and the Chinese
data set was only ∼15,000 years, which was associated
with a higher rate of population growth (table 4).
StudyK /KA S
To estimate the level of constraint of the FECH gene,
we aligned the orthologous human and chimpanzee (Pan
troglodytes) FECH sequences. Compared with the hu-
man consensus sequence, the chimpanzees show ﬁve
nonsynonymous mutations restricted to exon 2 (in co-
dons 24, 31, 39, and 45) that code for the signal peptide
targeting FECH in the mitochondria and three synon-
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Figure 4 Phylogeny of the IVS3-48C haplotypes presenting the
more parsimonious combination of single-site mutations and recom-
bination events. Each haplotype is represented by a circle, the area of
which represents the relative frequency of that haplotype amongst the
overall IVS3-48C haplotypes. Each circle is subdivided to show the
proportion of the individual haplotype frequency in each of the WF,
SEA, and WA population groups. The solid lines connect haplotypes
by single-site difference with precision of the position directly on the
line. Dashed lines denote recombination events. The root haplotype
(RH) is where the IVS3-48C mutation probably occurs. With a fre-
quency of 9%, RH is the second most frequent WA FECH haplotype.
The haplotype names are the same as in table 3.
ymous mutations in exon 3, 8, and 9 (in codons 100,
273, and 336) that code for the mature part of the pro-
tein (ﬁg. 1B). Considering only the coding part for the
mature protein, we observed a ratio of zero amino acid–
altering mutations (nonsynonymous, KA when normal-
ized to the number of relevant sites) to three silent mu-
tations (synonymous, KS).
Discussion
Extensive, ongoing research into low penetrance in sim-
ple Mendelian disorders is now beginning to bear fruit,
with important implications for the understanding of the
etiology of disease and for the development of new pre-
vention and treatment strategies. Environmental factors
and modiﬁer genes are often invoked as modulators of
the clinical expression of a gene defect at a major locus.
In EPP, for protoporphyrin to accumulate sufﬁciently to
cause clinical symptoms, a reduction in FECH activity
below a critical threshold of ∼35% is required. To ac-
count for this reduction, several mechanisms have been
suggested, including the coinheritance of either two trans
FECH gene defects or of one FECH defect and a com-
mon hypomorphic FECH allele (Gouya et al. 2002). To
determine the respective relevance of these mechanisms
to the clinical expression of EPP, we have conducted a
large retrospective and prospectivemutation and enzyme
study in EPP patients. In accordance with the generally
accepted autosomal dominant inheritance, most of the
patients have a single mutation restricted to one allele.
We achieved an overall detection rate of 83% (95 of
113 patients), which matches rates reported in previous
studies: Ru¨fenacht et al. (1998), using DGGE screening
in 29 Swiss and French EPP families (90%) and Whatley
et al. (2004), analyzing 14 British EPP patients (80%).
In 2 of 18 cases with an unidentiﬁed mutation, a seg-
regation study of 12 intragenic polymorphisms covering
the entire FECH gene reveals a large intragenic deletion
that is currently being characterized (data not shown).
It remains to be determined whether the other 16 neg-
ative cases simply correspond to a lack of sensitivity of
the method, to the location of mutations in unexplored
parts of the gene, or to major gene rearrangement. In
any case, in these families, the FECH assay is a valuable
tool for detecting asymptomatic carriers, since it appears
to provide a highly speciﬁc and sensitive diagnosis of
EPP. Indeed, in our study, the assays of FECH activity
identiﬁed all EPP carriers of a FECH gene defect whether
they were symptomatic or not ( ), and there wasnp 156
no overlap between healthy relatives and asymptomatic
patients. When both molecular and enzyme data were
used to analyze EPP families, the FECH assay unam-
biguously differentiated between the healthy subjects
(i.e., those without a mutant allele) and symptomatic or
asymptomatic carriers of a mutant FECH allele. In ad-
dition, the FECH assay is also sensitive enough to dis-
criminate between IVS3-48T/T and IVS3-48T/C groups
in normal subjects (ﬁg. 3). Furthermore, autosomal re-
cessive EPP patients, although clinically indistinguisha-
ble from those with the dominant form, could easily be
distinguished from them by this assay, since they had
residual FECH activity of !10%.
In animals, recessive inheritance is the rule, with cases
reported in bovines (Ruth et al. 1977), mice (Tutois et
al. 1991), and zebraﬁsh (Childs et al. 2000). In our co-
hort, 4% of patients with overt EPP presented a recessive
form of the disease, a frequency similar to that reported
by Whatley et al. (2004) in the United Kingdom (3%).
In the seven families with recessive EPP previously re-
ported, the mutations were mainly missense mutations
(Lamoril et al. 1991; Sarkany et al. 1994; Poh-Fitzpat-
rick et al. 2002; Whatley et al. 2004), and, in the three
new patients in our study, the mutations found were
always missense mutations, whereas, in dominant EPP,
missenses account for only 34.6% of all mutations.
Functional studies of missense mutations have shown
that those found in compound heterozygous subjects
have detectable residual activity, in contrast with those
found in dominant EPP, which are much lower or un-
detectable (Ru¨fenacht et al. 1998; Whatley et al. 2004).
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Table 4
Estimated Growth Rate and Age of the IVS3-48C Allele (with 95% CIs) in Three Different
Populations and in WF EPP families
Population rˆ gˆ
Age
(years)a
Japanese 1.027 (1.024–1.033) 529.0 (471.2–636.5) 13,225 (11,780–15,912)
Chinese 1.019 (1.017–1.024) 714.2 (634.9–849) 17,855 (15,872–21,225)
EPP Families 1.007 (1.006–1.009) 1,655.4 (1,431.7–2,055.3) 41,385 (35,792–51,382)
WF 1.004 (1.004–1.006) 2,431.0 (2,089.6–3,044.6) 60,775 (52,240–76,115)
a Assuming that one generation p 25 years.
Taken together with the low frequency of “null alleles”
in recessive EPP, these data highlight the absolute need
to maintain a minimum threshold level of heme biosyn-
thesis in cells. The extremely low FECH activity mea-
sured in the recessive forms could be a major risk factor
for hepatic effects. Severe liver disease occurs in 2% of
dominant forms (Bloomer 1988; Todd 1994; Meerman
2000) but in 30% of the 10 known EPP patients with
recessive inheritance. This shows how important it is to
detect patients with recessive inheritance. Nevertheless,
so far, three of our recessive EPP patients with the lowest
FECH activity (P1, P2, and P4) are still free of severe
hepatic injury, suggesting that other genetic or environ-
mental factors may also contribute to EPP liver
complications.
As a general detection strategy of the recessive forms
of EPP, Whatley et al. (2004) proposed ﬁrst to genotype
patients for the IVS3-48T/C polymorphism and to select
IVS3-48T homozygous patients for a complete muta-
tional analysis. Using this strategy, we would have
missed one of our four patients with recessive inheritance
(P1 in table 1). If applied in Japan, this strategy would
miss 160% of recessive cases, since the IVS3-48C allele
frequency is 42%. The best screening method remains
either the systematic molecular study of the entire FECH
gene, with a risk of missing one mutation in 15% of the
cases, or the lymphocyte FECH assay.
Dominant inheritance occurred in 95% of cases, and
the IVS3-48C low-expression mechanism was irrelevant
only in 2 of the 90 patients (12%). In one case, the
clinical manifestation of the disease may have been pre-
cipitated by an hepatic resection for adenoma that re-
duced the liver’s protoporphyrin clearance capacity. This
patient might otherwise have remained asymptomatic.
It will be of interest to follow her EPP symptomatology
after hepatic regeneration. These two mechanisms lead-
ing to overt EPP should be added to other rare mech-
anisms reported elsewhere that reduce FECH activity by
150%, such as acquired FECH gene mutations (Aplin
et al. 2001) or epigenetic control of FECH expression
(Onaga et al. 2004). As another physiopathological
mechanism, the possibility of dominant negative mu-
tations has been suggested on the basis of an EPP animal
model (Magness et al. 2002) or in vitro FECH expression
studies (Najahi-Missaoui and Dailey 2005; Ohgari et al.
2005) but remains to be stated in human EPP families.
In patient P5, the strict respect of the Mendelian rules
supports his classiﬁcation in the recessive form of EPP
(i.e., two mutations). Nevertheless, as described in the
“Results” section, the parent transmitting the Y191H
mutation shows a lymphocyte FECH activity in the nor-
mal range. If we consider the Y191H as deleterious, this
subject would be, in our experience, the ﬁrst carrier of
a FECH gene defect with a normal residual FECH ac-
tivity. In ﬁg. 3, we can observe that the mean FECH
activity between the IVS3-48T/T healthy relatives and
the IVS3-48T/C healthy relatives differ signiﬁcantly
(Mann-Whitney test, ) although there is a largeP ! .0001
overlap between the two groups. This indicates that, at
the individual level, a subject heterozygous for a wild-
type FECH allele and a hypomorphic FECH allele
(IVS3-48C allele or a mild missense mutation like the
Y191H mutant) is not distinguishable for FECH activity
from a subject carrying two wild-type FECH alleles.
The presence of the hypomorphic IVS3-48C common
allele trans to a mutated FECH allele appears to be gen-
erally required for clinical expression of EPP (197% of
the patients with autosomal dominant disease). Recent
studies in Japan, North America, Sweden, Israel, and the
United Kingdom all provide independent conﬁrmation
of the preeminence of this original mode of inheritance
(Yasui et al. 2002; Risheg et al. 2003; Schoenfeld et al.
2003;Wiman et al. 2003;Whatley et al. 2004).We could
also assess the role of the IVS3-48C allele low-expression
mechanism by analyzing the correlation between clinical
EPP prevalence and IVS3-48C allele frequency in dif-
ferent populations. We observed a north-south and east-
west gradient range from !1% in WA subjects to 31%
in SEA subjects and 43% in Japan (Human Genome
Center, Institute of Medical Science, University of To-
kyo). In a cohort of 60 EPP patients independent of the
113 families above, we have shown that the 11% IVS3-
48C allele frequency observed in France can account for
EPP penetrance and correlates to EPP prevalence. Kondo
et al. (2004) recently published extensive epidemiolog-
ical data on EPP in Japan. They showed that 51% of
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Japanese EPP cases occurred in families with some other
history of EPP, compared with only 15% ( ;2x p 28
) of French EPP cases, suggesting that the pen-4P ! 10
etrance of FECH mutations is higher in Japan. This
could be due to the IVS3-48C allele frequency of 43%
in Japan, which is four times higher than that in France.
Nevertheless, further studies in Japan are need to con-
ﬁrm the hypothesis. Moreover, to our knowledge, EPP
has never been demonstrated in black sub-Saharan Af-
ricans. Although melanodermy probably protects
against photosensitivity, other cutaneous porphyria af-
fect some black patients in South Africa (P. Meisner and
R. Hift, South African Porphyria Center, personal com-
munication). These ﬁndings support the proposal that
the low prevalence of EPP and the absence of the IVS3-
48C allele in the WA population may be linked, a notion
reinforced by the appparent absence of EPP cases in the
black African population living in France (data not
shown). It also suggests that diet, lifestyle, and other
nongenetic factors probably have no impact on EPP
penetrance. Altogether, we report convergent evidence
that overt EPP prevalence is dependent on IVS3-48C
allele frequency.
IVS3-48C allele frequency in the WA population is
very low, if not zero. The single HC1 haplotype found
in a Nigerian subject probably results from a recent ad-
mixture with Eurasian genes, as two alleles are restricted
to non-African populations. The ﬁve most common
IVS3-48C haplotypes can easily be connected, sharing
a restricted haplotype and the IVS3-48C allele that ap-
pears on a common RH African haplotype that differs
from HC5 only by the IVS3-48C allele. These obser-
vations strongly suggest that IVS3-48C alleles originate
from a founder effect that happened after the population
had moved out of Africa. Moreover, the study of a di-
nucleotide repeat (ATn) in intron 2 shows that, in 20
unrelated white EPP subjects, the IVS3-48C allele was
invariably associated with the A9 allele on the same
chromosome, whereas control white subjects are highly
polymorphic ( ; nine different alleles, data notnp 60
shown). This lack of IVS3-48C ATn variability suggests
rapid expansion after a bottleneck (Zietkiewicz et al.
2003). In SEA, the IVS3-48C allele frequency is asso-
ciated with a different IVS3-48C haplotype distribution
pattern (ﬁg. 4), which suggests independent expansions
that could correspond to the northern and southern
routes of migration referred to in the literature (Lahr
and Foley 1998; Kivisild et al. 1999). All these obser-
vations are compatible with the historically documented
Upper Paleolithic expansions dated 30,000–60,000
years ago. We then estimated the time of introduction
of the IVS3-48C allele more precisely on the basis of the
decay of allele association through time (Labuda et al.
1997; Austerlitz et al. 2003). By use of the WF or the
WF EPP families’ data sets, the estimates were ∼40,000–
60,000 years (assuming 25 years per generation), in ac-
cordance with our precedent estimation. Interestingly,
estimates based on populations with high IVS3-48C al-
lele frequency, like the Japanese and the Chinese pop-
ulations, seemed to give a more recent occurrence of
∼13,000–17,000 years. If we assume that the IVS3-48C
mutation occurred only once, this discrepancy can be
attributed to either a particular pattern of growth in the
SEA population or to the positive selection of IVS3-48C
haplotypes.
Finally, we estimated the neutrality of sequence dif-
ferences found between human and chimpanzee FECH
genes, by calculating the ratio of nonsynonymous to syn-
onymous mutations. Restricting our calculations to the
coding region for the mature part of the protein, we
found , indicating strongly negative Darwin-K /K p 0A S
ian selection of the mutant altering the function of the
protein. It remains to be seen whether the rapid expan-
sion across Asia of IVS3-48C haplotypes, despite a con-
text of a strongly negative impact on FECH function,
should be attributed to genetic drift alone or to positive
selection.
In conclusion, on the basis of molecular and enzyme
data, the conventional Mendelian rules of recessive and
dominant inheritance of a genetic trait appear to be too
restrictive in EPP. Several mechanisms appear to con-
tribute to bringing the residual FECH activity below the
critical threshold. In 190% of cases, overt EPP results
from the cosegregation of a severe mutation trans to the
hypomorphic IVS3-48C allele, and the high prevalence
in Europe, the United States, and Asia of the IVS3-48C
allele results in a pseudodominant inheritance of EPP.
The phylogenic origin of this common single SNP and
its geographic distribution mainly contribute to the clin-
ical expression of EPP. It remains to be seen whether
demographic events or selection explains the rapid ex-
pansion of IVS3-48C haplotypes across Asia. Finally, as
far as we are aware, EPP may be the only raremonogenic
trait for which the prevalence of overt disease is depen-
dent upon the frequency of a common variant, IVS3-
48T/C SNP, resulting from a unique mutational accident
that occurred 60,000 years ago.
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